Kala Pharmaceuticals Stock Fundamentals
| KALA Stock | USD 6.55 0.12 1.87% |
Kala Pharmaceuticals fundamentals help investors to digest information that contributes to Kala Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kala Stock. The fundamental analysis module provides a way to measure Kala Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kala Pharmaceuticals stock.
At present, Kala Pharmaceuticals' Research Development is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 66.1 M, whereas Interest Expense is forecasted to decline to about 4.9 M. Kala | Select Account or Indicator |
Kala Pharmaceuticals Company Return On Asset Analysis
Kala Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kala Pharmaceuticals Return On Asset | -0.4 |
Most of Kala Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kala Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Kala Total Assets
Total Assets |
|
Based on the latest financial disclosure, Kala Pharmaceuticals has a Return On Asset of -0.4025. This is 95.4% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The return on asset for all United States stocks is 187.5% higher than that of the company.
Kala Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kala Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kala Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kala Pharmaceuticals competition to find correlations between indicators driving Kala Pharmaceuticals's intrinsic value. More Info.Kala Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Kala Pharmaceuticals' Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kala Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Kala Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kala Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kala Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kala Pharmaceuticals by comparing valuation metrics of similar companies.Kala Pharmaceuticals is currently under evaluation in return on asset category among its peers.
Kala Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kala Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kala Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Kala Fundamentals
| Return On Equity | -2.48 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 17.48 M | ||||
| Shares Outstanding | 4.61 M | ||||
| Shares Owned By Insiders | 5.14 % | ||||
| Shares Owned By Institutions | 48.13 % | ||||
| Number Of Shares Shorted | 37.47 K | ||||
| Price To Earning | (0.52) X | ||||
| Price To Book | 4.32 X | ||||
| Price To Sales | 1.16 X | ||||
| Gross Profit | 1.33 M | ||||
| EBITDA | (36.08 M) | ||||
| Net Income | (42.2 M) | ||||
| Cash And Equivalents | 44.57 M | ||||
| Cash Per Share | 30.44 X | ||||
| Total Debt | 36.32 M | ||||
| Debt To Equity | 4.77 % | ||||
| Current Ratio | 2.54 X | ||||
| Book Value Per Share | 2.72 X | ||||
| Cash Flow From Operations | (27.93 M) | ||||
| Short Ratio | 1.91 X | ||||
| Earnings Per Share | (11.67) X | ||||
| Target Price | 15.0 | ||||
| Number Of Employees | 43 | ||||
| Beta | -2.14 | ||||
| Market Capitalization | 29.64 M | ||||
| Total Asset | 55.95 M | ||||
| Retained Earnings | (629.41 M) | ||||
| Working Capital | 44.52 M | ||||
| Current Asset | 84.65 M | ||||
| Current Liabilities | 10.53 M | ||||
| Net Asset | 55.95 M |
About Kala Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kala Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kala Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kala Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.1 M | 1 M | |
| Cost Of Revenue | 303 K | 287.9 K | |
| Stock Based Compensation To Revenue | 2.07 | 1.97 | |
| Sales General And Administrative To Revenue | 19.22 | 33.43 | |
| Research And Ddevelopement To Revenue | 5.22 | 4.96 | |
| Capex To Revenue | 0.09 | 0.09 | |
| Revenue Per Share | 2.30 | 4.20 | |
| Ebit Per Revenue | (18.81) | (19.75) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:Check out Kala Pharmaceuticals Piotroski F Score and Kala Pharmaceuticals Altman Z Score analysis. For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.67) | Quarterly Revenue Growth (1.00) | Return On Assets (0.40) | Return On Equity (2.48) |
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.